{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:30:54Z","timestamp":1791221454093,"version":"4.1.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clim.2020.108554","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T21:10:12Z","timestamp":1596834612000},"page":"108554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab"],"prefix":"10.1016","volume":"223","author":[{"given":"L.","family":"Rapisarda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Torti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"La Gamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sammarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2020.108554_bb0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108554_bb0010","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2020.108554_bb0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine- preventable infections and immunization in multiple sclerosis","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2020.108554_bb0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.msard.2019.04.004","article-title":"Immunization and multiple sclerosis: Reccomandation from the French multiple sclerosis society","volume":"31","author":"Lebrun","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2020.108554_bb0025","article-title":"Diabetes as a risk factor for herpes zoster in adults: a synthetic literature review","volume":"159","author":"Saadatian-Elhai","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"2","key":"10.1016\/j.clim.2020.108554_bb0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2015.08.008","article-title":"Vaccinations in adults with chronic inflammatory joint disease: immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs","volume":"83","author":"Morel","year":"2016","journal-title":"Joint Bone Spine"},{"issue":"41","key":"10.1016\/j.clim.2020.108554_bb0035","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1016\/j.vaccine.2007.07.051","article-title":"Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine","volume":"25","author":"Patterson-Bartlett","year":"2007","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.clim.2020.108554_bb0040","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJM196905292802201","article-title":"Prevention of varicella by zoster immune globulin","volume":"280","author":"Brunell","year":"1969","journal-title":"N. Engl. J. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620305775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620305775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:03:26Z","timestamp":1761494606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661620305775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":8,"alternative-id":["S1521661620305775"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2020.108554","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2020.108554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108554"}}